Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for investigation of NP-120 (Ifenprodil) for the treatment of chronic cough
  • Algernon filed an pre-IND meeting request in the event the company decides to move forward with a chronic cough Phase 2b study 
  • CEO Chris Moreau sat down with Dave Jackson to discuss the news
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent, trading at C$8.41 per share at 11:30 am EST

Algernon Pharmaceuticals (AGN) has received positive feedback from the U.S. FDA for its investigation of NP-120 (Ifenprodil) for the treatment of chronic cough.

Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B).

CEO Chris Moreau sat down with Dave Jackson to discuss the news.

On September 20, 2021, Algernon reported positive trending interim data from the chronic cough part of its 20-patient proof-of-concept Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough study being conducted in Australia and New Zealand.

Algernon has filed a pre-IND meeting request to seek guidance from the FDA in the event the company decides to move forward with a chronic cough Phase 2b study in the U.S. 

“We are very pleased with the response we received from the U.S. FDA. We look forward to the final data set from our IPF and chronic cough study so that we can plan our next steps.”

Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) is up 4.47 per cent, trading at C$8.41 per share at 11:30 am EST.

More From The Market Herald

" @ the Bell: Markets brace for interest rate hikes

Canada’s main stock index rallied to its fourth straight positive close on Wednesday, riding a push from the energy market and cannabis shares.

" Your Answer to the Formula Shortage Crisis (TSX: BABY)

 (Image via Else Nutrition Holdings Inc.)
Lexagene Holdings - CEO, Dr. Jack Regan.

" LexaGene (TSXV:LXG) announces multi-system purchase

LexaGene (LXG) announced that a large veterinary animal health corporation has purchased MiQLab Systems for two of its locations.

" Psyched Wellness (CSE:PSYC) sells non-core assets

Psyched Wellness (PSYC) has received $226,500 from the sale of two properties in northwestern Ontario.